News & Updates

Show Multimedia Only

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

20 Nov 2023

Oral naltrexone and acamprosate are associated with improved outcomes in individuals with alcohol use disorder and are supported as first-line pharmacotherapies in a meta-analysis.

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

20 Nov 2023

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023 by

Remdesivir and favipiravir does not appear to be heart-friendly in patients with COVID-19, according to a study presented at APSR 2023.

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Experts share essential updates on COVID-19 vaccines

20 Nov 2023 by

SARS-CoV-2 continues to evolve into newer variants. Post-Delta, these variants are generally more highly transmissible and immune-evasive, although not more virulent, said Dr Gregory Poland, Mary Lowell Leary Emeritus Professor of Medicine and director of Mayo Vaccine Research Group, Mayo Clinic in Rochester, Minnesota, US, at IDWeek 2023.

Experts share essential updates on COVID-19 vaccines

20 Nov 2023

Dementia risk heightened after stopping metformin treatment

18 Nov 2023 by

Metformin treatment discontinuation has been found to lead to increased incidence of dementia among older adults, and this association cannot be explained by changes in glucose control or insulin use.

Dementia risk heightened after stopping metformin treatment

18 Nov 2023

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

Among patients with heart failure (HF), those who have de novo HF have better outcomes than those who have worsening chronic HF status, but treatment with torsemide yields 12-month outcomes that are similar to that observed with furosemide regardless of HF type, according to a post hoc analysis of the TRANSFORM-HF trial.

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

COVID-19 vaccination during pregnancy protects babies against Omicron infection

17 Nov 2023 by

Receiving an mRNA vaccine during pregnancy appears to put newborns at low risk of SARS-CoV-2 infection with the Omicron variant through 6 months of age, according to a study from Singapore.

COVID-19 vaccination during pregnancy protects babies against Omicron infection

17 Nov 2023

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

17 Nov 2023 by

Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

17 Nov 2023

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

Remdesivir, favipiravir may not be heart-friendly

Remdesivir, favipiravir may not be heart-friendly

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D

Experts share essential updates on COVID-19 vaccines

Experts share essential updates on COVID-19 vaccines

Dementia risk heightened after stopping metformin treatment

Dementia risk heightened after stopping metformin treatment

Torsemide as good as furosemide for treating de novo, chronic heart failure

Torsemide as good as furosemide for treating de novo, chronic heart failure

COVID-19 vaccination during pregnancy protects babies against Omicron infection

COVID-19 vaccination during pregnancy protects babies against Omicron infection

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients